Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05061537 · ClinicalTrials.gov registry record · Phase 1
Study of PF-07263689 in Participants With Selected Advanced Solid Tumors
A Phase 1 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 1
- Development phase
- 13
- Enrollment target
NCT05061537 is a Phase 1 study that was terminated before completion, run by Pfizer. The registered enrollment target is 13 participants.
The verdict
NCT05061537, a Phase 1 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 13 participants
- Enrollment target
Study Summary
This is a first-in-human, Phase 1, open label, multicenter, multiple dose, dose escalation and expansion study intended to evaluate the safety, viral load kinetics and shedding, pharmacodynamic, and anti-tumor activity of PF-07263689, either alone or in combination with sasanlimab (an investigational anti-programmed cell death protein 1 \[PD-1\] antibody), in patients with selected locally advanced or metastatic solid tumors who have exhausted all available standard of care therapies available to them. The study consists of 2 parts: Part 1 dose escalation for PF-07263689 monotherapy (Part 1A) and in combination with sasanlimab (Part 1B), followed by Part 2 dose expansion for the combination therapy.
Interventions
- BIOLOGICAL Sasanlimab
- BIOLOGICAL PF-07263689
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2021-10-20 |
| Est. Completion | 2022-10-14 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05061537
The ClinicalTrials.gov registry entry for NCT05061537 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sasanlimab is the first listed.
NCT05061537 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05061537 about?
NCT05061537 is a clinical study titled "Study of PF-07263689 in Participants With Selected Advanced Solid Tumors". This is a first-in-human, Phase 1, open label, multicenter, multiple dose, dose escalation and expansion study intended to evaluate the safety, viral load kinetics and shedding, pharmacodynamic, and anti-tumor activity of PF-07263689, either alone or in combination with sasanlimab (an investigationa...
What is the current status of trial NCT05061537?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2021-10-20. Estimated completion is 2022-10-14.
What interventions are being tested in trial NCT05061537?
The interventions under investigation include: Sasanlimab (BIOLOGICAL), PF-07263689 (BIOLOGICAL).
Who is sponsoring clinical trial NCT05061537?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.